<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We reviewed the records and reevaluated 212 patients with <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> transplanted at the Fred Hutchinson <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Research Center (FHCRC) between 1970 and 1993 who survived &gt;/=2 years and who have been followed for up to 26 years </plain></SENT>
<SENT sid="1" pm="."><plain>Parameters analyzed included hematopoietic function, <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> (GVHD), <z:e sem="disease" ids="C0037274" disease_type="Disease or Syndrome" abbrv="">skin disease</z:e>, <z:hpo ids='HP_0000518'>cataracts</z:hpo>, <z:e sem="disease" ids="C0024115" disease_type="Disease or Syndrome" abbrv="">lung disease</z:e>, skeletal problems, posttransplant <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e>, <z:hpo ids='HP_0000716'>depression</z:hpo>, pregnancy/fatherhood, and the return to work or school, as well as patient self-assessment of physical and psychosocial health, social interactions, memory and concentration, and overall severity of symptoms </plain></SENT>
<SENT sid="2" pm="."><plain>Survival probabilities at 20 years were 89% for patients without (n = 125) and 69% for patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD (n = 86) (the status was uncertain in 1 surviving patient) </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients had <z:mpath ids='MPATH_458'>normal</z:mpath> hematopoietic parameters </plain></SENT>
<SENT sid="4" pm="."><plain>Skin problems occurred in 14%, <z:hpo ids='HP_0000518'>cataracts</z:hpo> in 12%, <z:e sem="disease" ids="C0024115" disease_type="Disease or Syndrome" abbrv="">lung disease</z:e> in 24%, and bone and joint problems in 18% of patients </plain></SENT>
<SENT sid="5" pm="."><plain>Eleven patients (12%) developed a <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumor</z:e> <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> and 19% of patients experienced <z:hpo ids='HP_0000716'>depression</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0011010'>Chronic</z:hpo> GVHD was the dominant risk factor for late complications </plain></SENT>
<SENT sid="7" pm="."><plain>Seventeen patients died at 2.5 to 20.4 years posttransplant; 13 of these had <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD and related complications </plain></SENT>
<SENT sid="8" pm="."><plain>At 2 years, 83% of patients had returned to school or work; the proportion increased to 90% by 20 years </plain></SENT>
<SENT sid="9" pm="."><plain>At least half of the patients preserved or regained the ability to become pregnant or father children </plain></SENT>
<SENT sid="10" pm="."><plain>Patients rated their quality of life as excellent and symptoms as minimal or mild </plain></SENT>
<SENT sid="11" pm="."><plain>In conclusion, marrow transplantation in patients with <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> established long-term <z:mpath ids='MPATH_458'>normal</z:mpath> hematopoiesis </plain></SENT>
<SENT sid="12" pm="."><plain>No new <z:e sem="disease" ids="C1521860" disease_type="Disease or Syndrome" abbrv="">hematologic disorders</z:e> occurred </plain></SENT>
<SENT sid="13" pm="."><plain>The major cause of morbidity and mortality was <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD </plain></SENT>
<SENT sid="14" pm="."><plain>However, the majority of patients who survived beyond 2 years returned to a fully functional life </plain></SENT>
</text></document>